Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2019
Price :
$35
*
At a glance
- Drugs Gedivumab (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Genentech
- 16 Nov 2018 Results published in the European Clinical Trials Database Registry
- 16 Nov 2018 Southe Korea was a planned location according to European Clinical Trials Database record.
- 12 Dec 2017 Status changed from active, no longer recruiting to completed.